27.42 USD
↗ 0.02 (0.07%)PRE MARKET (AS OF 06:35 AM EDT)
NewAmsterdam Pharma Company N.V. Ordinary Shares
NAMSNASDAQ • USD
Market: OPEN
Shares of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) are trading at $27.42. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Furthermore, NAMS is currently richly valued, trading at a premium to sector peers across key valuation metrics.
Technical & fundamental data as of Aug 26, 2026.
Open?$27.41
High?$27.42
Low?$27.41
Prev. Close?$27.40
Volume?1
Avg. Volume?1.1M
VWAP?$27.41
Rel. Volume?0.00x
Bid / Ask
Bid?$22.79 × 100
Ask?$33.86 × 100
Spread?$11.07
Midpoint?$28.33
Valuation & Ratios
Market Cap?3.3B
Shares Out?119.5M
Float?62.2M
Float %?53.2%
P/E Ratio?N/A
P/B Ratio?5.19
EPS?-$2.17
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Employees
100
Market Cap
3.3B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2022-11-23
Address
GOOIMEER 2-35
NARRDEN, P7 1411 DC
Phone: 35 206 2971
NARRDEN, P7 1411 DC
Phone: 35 206 2971
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?14
Short Sent.?15
Piotroski F-Score?0/9Weak
Altman Z-Score?25.03Safe
Confidence?55%Low
Short InterestSqueeze Risk
Short % of Float?20.34%Squeeze Risk
Short Interest?12.7M
Days to Cover?9.9
Free Float62.2M
Avg Daily Volume1.3M
Settlement Date2026-08-14
Financial Health
Current Ratio?9.03Strong
Quick Ratio?9.03Strong
Cash Ratio?5.81Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?5.19FAIR▾
Peers100
S&P36
P/S?459.95HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-11.7CHEAP▾
S&P97
EV/Sales?400.39HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-41.1%WEAK▾
S&P3
ROA?-36.8%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-143722000
Enterprise Value?$2.9B
Fundamentals ratios updated end of day